Gastrointestinal Cancer

Latest News

Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors
Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors

February 16th 2024

A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.

Irinotecan Liposome Approved by FDA for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Irinotecan Liposome Approved by FDA for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

February 13th 2024

Efineptakin Alfa Receives Orphan Drug Designation From FDA for Pancreatic Cancer
Efineptakin Alfa Receives Orphan Drug Designation From FDA for Pancreatic Cancer

February 5th 2024

Camrelizumab/Chemo Combo Improves Complete Responses in Locally Advanced ESCC
Camrelizumab/Chemo Combo Improves Complete Responses in Locally Advanced ESCC

January 21st 2024

Patients With ESCC Derive Survival Benefit With Tiragolumab Plus Atezolizumab and Chemotherapy
Patients With ESCC Derive Survival Benefit With Tiragolumab Plus Atezolizumab and Chemotherapy

January 20th 2024

Latest CME Events & Activities

Miami Breast 2024: Affiliated CE Symposia

March 7, 2024 - March 9, 2024

View More

A Focus on Acute Myeloid Leukemia

View More

The Latest on Acute Lymphocytic Leukemia

View More

Updates in Myelodysplastic Syndromes

View More

Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®

View More

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

8th Annual School of Nursing Oncology™

August 10, 2024

Register Now!

2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)

October 11-12, 2024

Register Now!

Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease

View More

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

More News

© 2024 MJH Life Sciences

All rights reserved.